Audit Committee | Position |
---|---|
Mitchell Chan
|
Chair
|
Jonathan Goldman, MD
|
Member
|
Kevin Lind
|
Member
|
Compensation Committee | Position |
---|---|
Aaron Kantoff
|
Chair
|
Rita Jain, MD
|
Member
|
Samantha Truex
|
Member
|
Nominating and Corporate Governance Committee | Position |
---|---|
Samantha Truex
|
Chair
|
Aaron Kantoff
|
Member
|
Gilla Kaplan, PhD
|
Member
|
Science and Technology Committee | Position |
---|---|
Rita Jain, MD
|
Chair
|
Jonathan Goldman, MD
|
Member
|
Gilla Kaplan, PhD
|
Member
|
Mitchell Chan
Jonathan Goldman, MD
Kevin Lind
Mr. Lind is a seasoned biotechnology executive with more than 20 years of leadership experience. He most recently served as President, Chief Executive Officer, and Board Member of Longboard Pharmaceuticals, where he led and transformed the Arena spinout into a leader in neurology and oversaw its $2.6 billion acquisition by H. Lundbeck A/S in 2024. Prior to his time at Longboard, Mr. Lind was Executive Vice President and Chief Financial Officer at Arena Pharmaceuticals, where he played a central role in its turnaround, including lucrative business development partnerships and execution of its spinout of Longboard in 2020. Over the course of his career, Mr. Lind has raised more than a billion dollars in capital to support innovative biotech companies. He began his career in investment banking at Lehman Brothers before joining TPG, where he focused on healthcare investing. In addition to his role with Avalo, Mr. Lind currently serves as Chairman of the Board of Apnimed, Inc. He received a BS from Stanford University in Biological Sciences and an MBA from UCLA Anderson School of Management.